March 2026 in “RS Global journals (RS Global Sp. z O.O.)” This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.
9 citations
,
January 2017 in “Farmacia” This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.
1 citations
,
November 2016 in “Journal of the Dermatology Nurses’ Association” This article reviews the mechanism, use, and alternatives for finasteride in dermatology and provides no new clinical results.
January 2016 in “Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)” This study aims to develop three topical formulations of finasteride to reduce its side effects for treating androgenic alopecia.
June 2007 in “Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii” This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.
29 citations
,
December 1998 in “Seminars in Cutaneous Medicine and Surgery” This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.